Givosiran is another example of the developed RNAi based therapeutic agent loaded in lipid NPs to reduce the expression of delta aminolevulinic acid synthase 1 (ALAS1) gene and hence treating acute Intermittent porphyria (AIP). The gene discussed is ALAS1; the disease is acute intermittent porphyria.